{"name":"Yong Seog Oh","slug":"yong-seog-oh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Intermittent heparin infusion","genericName":"Intermittent heparin infusion","slug":"intermittent-heparin-infusion","indication":"Venous thromboembolism prevention","status":"phase_3"},{"name":"Continuous heparin infusion","genericName":"Continuous heparin infusion","slug":"continuous-heparin-infusion","indication":"Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Adenosine arm","genericName":"Adenosine arm","slug":"adenosine-arm","indication":"Other","status":"phase_3"},{"name":"Indenol","genericName":"Indenol","slug":"indenol","indication":"Other","status":"discontinued"}]}],"pipeline":[{"name":"Intermittent heparin infusion","genericName":"Intermittent heparin infusion","slug":"intermittent-heparin-infusion","phase":"phase_3","mechanism":"Intermittent heparin infusion prevents blood clot formation by inhibiting thrombin and other coagulation factors through periodic intravenous administration.","indications":["Venous thromboembolism prevention","Acute coronary syndrome","Atrial fibrillation with thromboembolism risk"],"catalyst":""},{"name":"Adenosine arm","genericName":"Adenosine arm","slug":"adenosine-arm","phase":"phase_3","mechanism":"Adenosine arm likely refers to a therapeutic strategy leveraging adenosine signaling pathways, potentially for immunomodulation or cardioprotection.","indications":[],"catalyst":""},{"name":"Continuous heparin infusion","genericName":"Continuous heparin infusion","slug":"continuous-heparin-infusion","phase":"phase_3","mechanism":"Heparin is an anticoagulant that inhibits multiple clotting factors to prevent thrombus formation.","indications":["Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism)","Acute coronary syndrome","Atrial fibrillation with thromboembolism risk","Prevention of thrombosis during cardiac surgery and extracorporeal circulation"],"catalyst":""},{"name":"Indenol","genericName":"Indenol","slug":"indenol","phase":"discontinued","mechanism":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE1ldjNZb2ZTbDJ0eTNxcllLb0dVelhEUFoxLVNfZkRXS3pjcno1YXgxbU41b0xWVXBPQ1N3Y1YycHpXR3l0a0JqWENEWDU4dHB4OHBBWUYwR09ELUhMOEVJZw?oc=5","date":"2024-09-01","type":"trial","source":"NEJM","summary":"Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease - NEJM","headline":"Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":3,"discontinued":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}